Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.

To enhance the success of tumor immunotherapy in clinical trials, it is important to develop protein degraders, allosteric inhibitors, and antibody-drug conjugates based on the crystal structure of HPK1, and to explore combination therapy approaches. Although several challenges remain, development of HPK1 inhibitors display promising in preclinical and clinical studies.